| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; and
Laboratory for Immunological Research, Schering-Plough, Dardilly, France
Corticosteroids (CS) have been shown to exert strong inhibitory effects on dendritic cell (DC) differentiation and function. Those studies were mostly performed with monocyte-derived DC, which represents only one subpopulation from the wide variety of DC types. In the present study the effects of the CS dexamethasone and prednisolone were investigated on the differentiation of CD34+ hemopoietic progenitor cells into 1) Langerhans cells (LC), which differentiate directly into CD1a+ DC; and 2) dermal/interstitial DC, which differentiate via a CD14+CD1a- phenotype into CD14-CD1a+ DC. CS present during the entire 11-day culture period, resulting in fully differentiated CD1a+ DC, increased the percentage of langerin+ DC within the CD1a+ population. In line with these data, CS treatment during the first 6 days of differentiation reduced the development of CD14+ dermal DC precursors and thereby seemed to support the generation of CD1a+ LC precursors. Addition of CS from day 6 onward specifically blocked the development of CD1a+ dermal DC by both inhibition of spontaneous and IL-4-induced differentiation of CD14+ DC precursors into CD1a+ DC as well as induction of apoptosis in CD14+ DC precursors. Apoptosis was not found in CD14+ macrophage precursors derived from the same CD34+ progenitors. The development and function of LC were not affected by CS, as demonstrated by a normal T cell stimulatory capacity and IL-12 production. These data demonstrate that CS interfere with the normal development of DC from CD34+ progenitors by specific induction of apoptosis in precursors of dermal/interstitial DC. In view of the different functional capacities of dermal/interstitial DC and Langerhans cells, this might affect the overall cellular immune response.
This article has been cited by other articles:
|
|
 |
|
  J A Hardin Dendritic cells: potential triggers of autoimmunity and targets for therapy Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv86 - iv90. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen, T. Murakami, J. J. Oppenheim, and O. M. Z. Howard Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking Blood, October 1, 2005; 106(7): 2409 - 2416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Kooten and A. M. Woltman CD40 brings the shuttle down Blood, September 15, 2005; 106(6): 1895 - 1896. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kahaly, S. Pitz, G. Hommel, and M. Dittmar Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves' Orbitopathy J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5234 - 5240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Wiley, M. Cwiartka, D. Alvarez, D. C. Mackenzie, J. R. Johnson, S. Goncharova, L. Lundblad, and M. Jordana Transient Corticosteroid Treatment Permanently Amplifies the Th2 Response in a Murine Model of Asthma J. Immunol., April 15, 2004; 172(8): 4995 - 5005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Woltman and C. van Kooten Functional modulation of dendritic cells to suppress adaptive immune responses J. Leukoc. Biol., April 1, 2003; 73(4): 428 - 441. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
